医学
内科学
危险系数
卵巢癌
胃肠病学
叶酸受体
人口
无进展生存期
随机对照试验
阿霉素
化疗
癌症
泌尿科
肿瘤科
置信区间
癌细胞
环境卫生
作者
R. Wendel Naumann,Robert L. Coleman,Robert A. Burger,Edward A. Sausville,E. Kutarska,Sharad Ghamande,Nashat Gabrail,Stephen DePasquale,Elżbieta Nowara,Lucy Gilbert,Robert H. Gersh,Michael Teneriello,Wael A. Harb,Panagiotis A. Konstantinopoulos,Richard T. Penson,James T. Symanowski,C. Lovejoy,Christopher P. Leamon,David Morgenstern,Richard A. Messmann
标识
DOI：10.1200/jco.2013.49.7685
摘要
Vintafolide plus PLD is the first combination to demonstrate an improvement over standard therapy in a randomized trial of patients with platinum-resistant ovarian cancer. Etarfolatide can identify patients likely to benefit from vintafolide.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
GingerF
Ethan
郭竞阳
AllRightReserved
愔愔
嘻嘻哈哈
贪玩的秋柔
Criminology34
OsamaKareem
arbitmomo
YifanWang
无极微光
Tong
Moonpie
淡然的新晴
fearless
小宋
嘉心糖
Hayat
Nexus
皖公网安备34019202002308
